natgillin/translations-raw huggingface dataset:
Children taking Lamivudine/Zidovudine Teva should be closely monitored for side effects.
Otroke, ki jemljejo zdravilo Lamivudine/Zidovudine Teva, je treba skrbno nadzorovati glede pojava neželenih učinkov.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine/Zidovudine Teva.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Therefore, the CHMP's view was that, as for Combivir, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Combivir odtehtajo znana tveganja.
They both work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Učinkovini podobno zavirata delovanje reverzne transkriptaze, tj. encima, ki ga tvori virus HIV in ki omogoča okužbo celic ter nastajanje novih virusov.
The CHMP concluded that, in accordance with EU requirements, Lamivudine/Zidovudine Teva has been shown to have comparable quality and to be bioequivalent to Combivir.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Lamivudine/Zidovudine Teva primerljivo raven kakovosti kot zdravilo Combivir ter da mu je biološko enakovredno.
Both active substances in Lamivudine/Zidovudine Teva, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
Obe zdravilni učinkovini v zdravilu Lamivudine/Zidovudine Teva, lamivudin in zidovudin, sta zaviralca nukleozidne reverzne transkriptaze (NRTI).
Because Lamivudine/Zidovudine Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Combivir.
Ker je zdravilo Lamivudine/Zidovudine Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Combivir.
What are the benefits and risks of Lamivudine/Zidovudine Teva?
Kakšne so koristi in tveganja, povezani z zdravilom Lamivudine/Zidovudine Teva?
Lamivudine/Zidovudine Teva is a ‘generic medicine'.
Zdravilo Lamivudine/Zidovudine Teva je „generično zdravilo“.
Treatment with Lamivudine/Zidovudine Teva should be started by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Lamivudine/Zidovudine Teva lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
The Committee recommended that Lamivudine/Zidovudine Teva be given marketing authorisation.
Priporočil je, da se za zdravilo Lamivudine/Zidovudine Teva izda dovoljenje za promet.
Other information about Lamivudine/Zidovudine Teva
Druge informacije o zdravilu Lamivudine/Zidovudine Teva
Lamivudine/Zidovudine Teva is used in combination with at least one other HIV medicine to treat patients infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Lamivudine/Zidovudine Teva se uporablja za zdravljenje bolnikov, ki so okuženi z virusom humane imunske pomanjkljivosti (HIV), to je virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids), v kombinaciji z vsaj enim drugim zdravilom za zdravljenje te okužbe.
Why has Lamivudine/Zidovudine Teva been approved?
Zakaj je bilo zdravilo Lamivudine/Zidovudine Teva odobreno?
What is Lamivudine/Zidovudine Teva?
Kaj je zdravilo Lamivudine/Zidovudine Teva?
How has Lamivudine Zidovudine Teva been studied?
Kako je bilo zdravilo Lamivudine/Zidovudine Teva raziskano?
What is Lamivudine/Zidovudine Teva used for?
Za kaj se zdravilo Lamivudine/Zidovudine Teva uporablja?
How is Lamivudine/Zidovudine Teva used?
Kako se zdravilo Lamivudine/Zidovudine Teva uporablja?
How does Lamivudine/Zidovudine Teva work?
Kako zdravilo Lamivudine/Zidovudine Teva deluje?
Ref.: EMEA/484536/2009 EMEA/H/C/1018
: EMEA/484536/2009 EMEA/H/C/1018
It is available as white capsules (200 mg).
Na voljo je v obliki kapsul bele barve (200 mg).
It should only be taken by patients weighing at least 47 kg.
Jemljejo ga lahko le bolniki, ki tehtajo več kot 47 kg.
This means that it is similar to a ‘reference medicine' already authorised in the European Union (EU) called Rebetol.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Rebetol.
The duration of treatment depends on the patient's condition and response to treatment, and ranges from 24 weeks to a year.
Trajanje zdravljenja je odvisno od bolnikovega stanja in odziva na zdravljenje, in sicer od 24 tednov do enega leta.
Ribavirin Teva is taken with food each day in two divided doses (morning and evening).
Zdravilo Ribavirin Teva se jemlje s hrano vsak dan v dveh deljenih odmerkih (zjutraj in zvečer).
It can also be used in adults who previously responded to treatment with interferon alfa but whose disease has come back.
Uporablja se lahko tudi pri bolnikih, ki so se v preteklosti odzvali na zdravljenje z interferonom, a se je bolezen ponovila.
Ribavirin Teva must never be used on its own but only together with interferon alfa-2b (another medicine used in hepatitis).
Zdravilo Ribavirin Teva se ne sme nikoli uporabljati samostojno, temveč samo v kombinaciji z interferonom alfa-2b (drugim zdravilom, ki se uporablja pri hepatitisu).
The dose of Ribavirin Teva is based on the patient's body weight, and ranges from three to seven capsules a day.
Odmerek zdravila Ribavirin Teva je določen na osnovi bolnikove telesne mase in znaša od tri do sedem kapsul na dan.
Ribavirin Teva is a ‘generic medicine'.
Ribavirin Teva je „generično zdravilo“.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ribavirin Teva has been shown to have comparable quality and to be bioequivalent to Rebetol.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Ribavirin Teva primerljivo raven kakovosti kot zdravilo Rebetol ter da mu je biološko enakovredno.
What are the benefit and risk of Ribavirin Teva?
Kakšne so koristi in tveganja, povezana z zdravilom Ribavirin Teva?
Ribavirin Teva on its own has no effect on eliminating the hepatitis C virus from the body.
Zdravilo Ribavirin Teva kot samostojno zdravilo nima nobenega učinka na odstranitev virusa hepatitisa C iz telesa.
Ribavirin Teva is used to treat patients aged three years and older who have chronic (long-term) hepatitis C (a disease of the liver due to an infection with the hepatitis C virus).
Zdravilo Ribavirin Teva se uporablja za zdravljenje bolnikov, starih tri leta ali več, ki imajo kronični (dolgotrajni) hepatitis C (bolezen jeter zaradi okužbe z virusom hepatitisa C).
The Committee recommended that Ribavirin Teva be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Ribavirin Teva odobri dovoljenje za promet.
Treatment with Ribavirin Teva should be started and monitored by a doctor who has experience in the management of chronic hepatitis C.
Zdravljenje z zdravilom Ribavirin Teva mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa C.
Therefore, the CHMP's view was that, as for Rebetol, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Rebetol, odtehtajo znana tveganja.
Other information about Ribavirin Teva:
Druge informacije o zdravilu Ribavirin Teva:
Ribavirin Teva is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Zdravilo Ribavirin Teva naj bi vplivalo na nastajanje ali delovanje virusne DNK in RNK, brez katerih virusi ne morejo preživeti ali se razmnoževati.
Because Ribavirin Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je Ribavirin Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, se šteje, da ima enake koristi in tveganja kot referenčno zdravilo.
Because Ribavirin Teva is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine.
Ker je zdravilo Ribavirin Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu.
Ribavirin Teva is a medicine that contains the active substance ribavirin.
Ribavirin Teva je zdravilo, ki vsebuje zdravilno učinkovino ribavirin.
The dose may need to be adjusted for patients who experience side effects.
Pri bolnikih, pri katerih se pojavijo neželeni učinki, je odmerek morda treba prilagoditi.
The European Commission granted a marketing authorisation valid throughout the EU for Ribavirin Teva to Teva Pharma B.V. on 31 March 2009.
Evropska komisija je dovoljenje za promet z zdravilom Ribavirin Teva, veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma B.V.
The active substance in Ribavirin Teva, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'.
Zdravilna učinkovina zdravila Ribavirin Teva, ribavirin, je protivirusna učinkovina, ki spada v razred nukleozidnih analogov.
The full EPAR for Ribavirin Teva can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ribavirin Teva je na voljo tukaj.
Why has Ribavirin Teva been approved?
Zakaj je bilo zdravilo Ribavirin Teva odobreno?
Ribavirin Teva can be used in ‘naïve' patients (who have not been treated before) for all types of hepatitis C except for genotype 1.
Zdravilo Ribavirin Teva se lahko uporablja za vrste hepatitisa C, razen za genotip 1, pri bolnikih, ki še nikoli niso bili zdravljeni.
How has Ribavirin Teva been studied?
Kako je bilo zdravilo Ribavirin Teva raziskano?
What is Ribavirin Teva used for?
Za kaj se zdravilo Ribavirin Teva uporablja?
What is Ribavirin Teva?
Kaj je zdravilo Ribavirin Teva?
How is Ribavirin Teva used?
Kako se zdravilo Ribavirin Teva uporablja?
How does Ribavirin Teva work?
Kako zdravilo Ribavirin Teva deluje?
ATCvet code: QP54AA05.
Oznaka ATC vet: QP54AA05.
Do not use in animals under 6 weeks of age.
Ne uporabite pri živalih, mlajših od 6 tednov.
Images for optional inclusion should space allow
Slike za izbirno vključitev če bo prostor omogočal
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/).
Date of first authorisation: 17/04/2019
Datum pridobitve dovoljenja za promet: 17/04/2019
Periodic safety update report (PSUR) submissions shall be synchronised and submitted at the same frequency as for the reference product.
Predloge za redno posodobljeno varnostno poročilo (PSUR) je treba sinhronizirati in predložiti enako pogosto kot referenčno zdravilo.
Used applicators should be disposed of immediately and not left within the sight or reach of children.
Uporabljene aplikatorje je treba takoj odstraniti in ne puščati na dosegu otrok.
On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children.
Na dan, ko živalim date zdravilo, se morajo otroci izogibati stiku z živalmi in živali ne smejo spati skupaj s svojimi lastniki, še posebej z otroki.
Pharmacotherapeutic group: antiparasitic products, insecticides and repellents, macrocyclic lactones.
Farmakoterapevtska skupina: antiparazitiki, insekticidi in repelenti, makrociklični laktoni.
This inhibits the electrical activity of nerve cells in nematodes and muscle cells in arthropods leading to their paralysis and/or death.
To inhibira električno aktivnost živčnih celic nematodov in mišičnih celic artropodov in vodi k njihovi paralizi in/ali smrti.
Selamectin may adversely affect fish or certain water-borne organisms on which they feed.
Selamektin lahko negativno učinkuje na ribe ali določene vodne organizme, s katerimi se ribe prehranjujejo.
Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
Ne uporabite pri mačkah, ki imajo sočasno tudi druge bolezni ali pri mačkah, ki so močno oslabljene ali imajo prenizko telesno maso (glede na velikost in starost).
Butylated hydroxytoluene (E321) 0.08%.
Pomožne snovi: butilhidroksitoluen (E321) 0,08%.
11 PROHIBITION OF SALE, SUPPLY AND/OR USE
PREPOVED PRODAJE, OSKRBE IN/ALI UPORABE
People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the product with caution.
Osebe z občutljivo kožo ali znano preobčutljivostjo na tovrstna zdravila naj s tem zdravilom ravnajo previdno.
This product is not effective against adult D. immitis.
Zdravilo ne učinkuje na odrasle oblike D. immitis.
The veterinary medicinal product is presented in a white plastic pipette formed from a layer of polypropylene/cyclic olefin copolymer/polypropylene with a layer of polyethylene/ethylene vinyl alcohol/polyethylene.
Zdravilo za uporabo v veterinarski medicini je predstavljeno v beli plastični merilni kapalki, ki je izdelana iz plasti polipropilenskega / cikličnega kopolimera / polipropilena s plastjo polietilena / etilen vinil alkohola / polietilena.
Incompatibilities Not applicable.
Inkompatibilnosti: Ni smiselno.
The product should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Chanhold ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot.
Konico merilne kapalke položite na kožo in merilno kapalko večkrat stisnite, da se vsebina popolnoma in neposredno na koži na enem mestu popolnoma izprazni.
Do not smoke, eat or drink while handling the product.
Med uporabo zdravila ni dovoljeno jesti, piti ali kaditi.
Do not administer orally or parenterally.
Zdravila ne smemo dajati peroralno ali parenteralno.
Containers and residual contents should be disposed of along with collected domestic refuse to avoid contamination of any water courses.
Vsebniki in ostanki vsebine se morajo odlagati v sistem zbiranja gospodinjskih odpadkov, da se izognemo onesnaženju vodnih virov.
This is normal and will disappear typically within 24 hours of treatment administration and does not affect either the safety or efficacy of the veterinary medicinal product.
Pojav je običajen in izgine v 24 urah po nanosu in ne vpliva na varnost niti na učinkovitost zdravila za uporabo v veterinarski medicini.
• Treatment and prevention of flea infestations caused by Ctenocephalides spp.
• Zdravljenje in preprečevanje infestacij z bolhami, ki jih povzročajo vrste Ctenocephalides spp.
Selamectin paralyses and/or kills a wide range of invertebrate parasites through interference with their chloride channel conductance causing disruption of normal neurotransmission.
Selamektin povzroča paralizo in/ali pogin širokega spektra parazitov (nevretenčarjev) z oviranjem prevodnosti klorovih kanalov, kar povzroči motnje v normalni nevrotransmisiji.
Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.
Zdravljene živali naj se ne zadržujejo v bližini ognja in drugih virov vžiga najmanj 30 minut po dajanju zdravila ali dokler dlaka ni suha.
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Rok uporabnosti zdravila v pakiranju za prodajo: 2 leta.
A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Priporočamo, da veterinar ponovno pregleda žival 30 dni po prvem zdravljenju, ker je pri nekaterih živalih potrebeno še drugo zdravljenje.
• Treatment of biting lice infestations (Felicola subrostratus)
• Zatiranje infestacij z ušmi (Felicola subrostratus)
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
B POGOJI TER OMEJITVE GLEDE OSKRBE IN UPORABE
This veterinary medicinal product is to be applied to the skin surface only.
Zdravilo za uporabo v veterinarski medicini nanašamo le na površino kože.
Medicines should not be disposed of via wastewater.
Ne odvrzite zdravila v odpadno vodo.
Butylated hydroxytoluene (E321) Dipropylene glycol methyl ether Isopropyl alcohol
Seznam pomožnih snovi butilhidroksitoluen (E321) dipropilen glikol metil eter izopropilalkohol
Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na zunanji ovojnini.
Potency (mg/ml)
Koncentracija selamektina (mg/ml)
The appropriate length of the treatment period for individual parasites is specified below.
Ustrezen čas zdravljenja za posamezne parazite je naveden v spodnji tabeli.
On very rare occasions transient focal irritation may also be observed.
V zelo redkih primerih so opazili tudi prehodno draženje kože.
It is important to apply the dose as indicated to minimise the quantity that the animal can lick off.
Pomembno je, da odmerek nanesemo točno po navodilih; tako količino, ki bi jo žival lahko polizala, kar najbolj zmanjšamo.
When concurrent infestations or infections in the same animal are to be treated with the veterinary medicinal product, only one application of the recommended 6 mg/kg dose should be administered at any one time.
Kadar je treba z zdravilom za uporabo v veterinarski medicini zdraviti hkratne infestacije ali infekcije pri isti živali, dajemo naenkrat le enkraten priporočen odmerek 6mg/kg.
On rare occasions in cats and dogs, application of the veterinary medicinal product may produce a local temporary clumping of the hair at the application site and/or an occasional appearance of a small quantity of a white powder.
V redkih primerih lahko nanos zdravila za uporabo v veterinarski medicini pri mačkah in psih povzroči lokalno začasno zlepljanje dlake na mestu nanosa ali občasen pojav manjših količin belega prahu.
Cats and dogs:
Mačke in psi:
Avoid direct contact with treated animals until the application site is dry.
Izogibajte se neposrednemu stiku z zdravljenimi živalmi, dokler območje nanosa ni suho.
• Treatment of ear mites (Otodectes cynotis).
• Zatiranje ušesnih garij (Otodectes cynotis).
Part the animal's coat at the base of the neck in front of the shoulder blades until the skin is visible.
Razprite dlako na hrbtni strani živali, na vratu pred lopaticami, dokler koža ni vidna.
This is as a result of the adulticidal, larvicidal and ovicidal properties of the product.
To je rezultat adulticidnega, larvicidnega in ovicidnega delovanja zdravila.
Appropriate combination of pipettes
Ustrezna kombinacija merilnih kapalk
If accidental eye exposure occurs, flush the eyes immediately with water and seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru stika zdravila z očmi, jih takoj izperite z obilo vode ter se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino
Very rarely, as with other macrocyclic lactones, reversible neurological signs, including seizures, have been observed after use of the veterinary medicinal product in both dogs and cats.
Zelo redko, tako kot pri drugih makrocikličnih laktonih, so tudi po uporabi tega zdravila za uporabo v veterinarski medicini pri psih in mačkah opazili reverzibilne nevrološke znake vključno z epileptičnimi napadi.
Avoid contact between the product and your fingers.
Pazimo, da zdravilo ne pride v stik z našimi prsti.
3 pipettes 6 pipettes
3 merilne kapalke 6 merilnih kapalk
If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of the veterinary medicinal product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms.
Če smo kakšen odmerek izpustili in mesečni presledek med dvema odmerkoma prekoračili, bomo s takojšnjim dajanjem zdravila za uporabo v veterinarski medicini in s ponovnim mesečnim odmerjanjem možnost razvoja odraslih oblik parazita zmanjšali na najmanjšo možno mero.
• Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration.
• Preprečevanje obolenj zaradi infekcij z mikrofilarijami, povzročenih z Dirofilarie immitis, z mesečnim nanosom.
Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette.
Pretresite ozek del merilne kapalke, da zagotovite, da vsebina ostane v glavnem delu merilne kapalke.
Snap back the tip.
Prelomite konico s potegom nazaj.
Cats and dogs weighing 2.5 kg or less
Mačke in psi s telesno maso do 2,5 kg ali manj.
The product is available in packs of three pipettes (all strengths), six pipettes (all strengths except 15 mg), or fifteen pipettes (15 mg strength only) in individual foil sachets within an outer carton.
Zdravilo je na voljo v pakiranjih s tremi merilnimi kapalkami (vse jakosti), šestimi merilnimi kapalkami (vse jakosti razen 15 mg) ali petnajstimi merilnimi kapalkami (samo 15 mg jakosti) v posameznih vrečicah iz folije v zunanji škatli.
The product has been tested with no other adverse reactions in over 100 different pure and mixed breeds of dogs including Collies, and in mixed breeds and 16 pure breeds of cats.
Zdravilo so testirali pri več kot 100 različnih čistih in mešanih pasmah psov, vključno s koliji ter 16 čistih pasmah mačk in niso odkrili nobenih drugih stranskih učinkov.
The systemic persistence of selamectin in plasma and the lack of extensive metabolism provide effective concentrations of selamectin for the duration of the inter-dosing interval (30 days).
Podaljšano vztrajanje selamektina v plazmi in neintenziven metabolizem zagotavljata učinkovite koncentracije za celotno obdobje med dvema nanosoma (30 dni).
For ear mite treatment, do not apply directly to the ear canal.
Za zdravljenje ušesnih garij zdravila ne nanašamo neposredno v ušesni kanal.
How to apply:
Način uporabe:
Selamectin was also administered at 3 times the recommended dose to breeding male and female cats and dogs, including pregnant and lactating females nursing their litters and at 5 times the recommended dose to ivermectin-sensitive Collies, and no undesirable effects were observed.
Selamektin so v trikratnem priporočenem odmerku uporabljali pri mačjih in pasjih samcih in samicah za vzrejo, vključno z brejimi in doječimi živalmi, ki imajo leglo z mladiči in v petkratnem priporočenem odmerku pri kolijih, občutljivih za ivermektin, vendar niso opazili nobenih neželenih učinkov.
The prolonged persistence and slow elimination of selamectin from plasma is reflected in the terminal elimination half-life values of 8 and 11 days in cats and dogs respectively.
Podaljšano vztrajanje in postopno izločanje selamektina iz plazme ima za posledico polovično razpolovno dobo do končnega izločenja v trajanju 8 dni pri mačkah oziroma 11 dni pri psih.
Apply to the skin at the base of the neck in front of the shoulder blades.
Nanesite na kožo na predel zatilja, pred lopatici.
The product is ovicidal for 3 weeks after administration.
Zdravilo deluje ovicidno 3 tedne po aplikaciji.
Hold the pipette upright.
Držite merilno kapalko pokonci.
If significant licking occurs, a brief period of hypersalivation may rarely be observed in cats.
Pri znatnejšem lizanju se lahko pri mačkah redko pojavi kratkotrajno pretirano slinjenje.
Do not allow treated animals to bathe in water courses until at least two hours after treatment administration.
Drugi previdnostni ukrepi Zdravljene živali se najmanj dve uri po dajanju zdravila ne smejo kopati v vodotokih.